Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | STEAP1 targeting CAR for adoptive cell therapy against cancer

Jon Amund Kyte • 9 Sep 2022
ESMO 2022
General Genitourinary Cancer Prostate Cancer CAR-T

Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway, discusses the development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. STEAP1 CAR exhibits potent in vitro and in vivo functionality and can be further developed for potential clinical use. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Jon Amund Kyte

2:05
Immunotherapy in breast cancer
Jon Amund Kyte • 8 Dec 2022
4:38
ALICE: atezolizumab + immunogenic chemotherapy in metastatic TNBC
Jon Amund Kyte • 8 Dec 2022
2:17
STEAP1 targeting CAR-T therapy for solid tumors
Jon Amund Kyte • 8 Dec 2022
0:58
Small randomized trials to investigate optimal chemotherapy and immunotherapy combinations
Jon Amund Kyte • 11 Sep 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals